Results From STRIVE Trial Of Enzalutamide Versus Bicalutamide In CRPC Published In Journal Of Clinical Oncology
27
Jan
Castration-resistant prostate cancer is a fatal form of prostate cancer, the prognosis is poor, with a median survival time of 12 to 18 months. China is still a lack of effective means of treatment of CRPC. In this paper, bicalutamide … Read More »